[{"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-001", "question": "A 68-year-old man is 18 days post-Ivor Lewis esophagectomy with gastric conduit reconstruction for stage III esophageal adenocarcinoma. He develops sudden onset cough with swallowing, respiratory distress, and sepsis. Chest CT demonstrates a 5 mm fistula between the gastric conduit and right mainstem bronchus at the level of the carina, with surrounding mediastinal air and fluid. Bronchoscopy confirms the fistula with conduit mucosa visible. What is the definitive management?", "options": ["A) Endoscopic placement of overlapping esophageal and airway stents", "B) Emergency right thoracotomy with fistula repair using intercostal muscle flap and conduit resection with cervical esophagostomy", "C) NPO status, total parenteral nutrition, and broad-spectrum antibiotics for 6 weeks", "D) Bronchoscopic application of fibrin glue and continued enteral feeding via jejunostomy", "E) Cervical esophagostomy and conduit abandonment without fistula repair"], "answer": "B", "answer_index": 1, "explanation": "Early postoperative tracheobronchial-gastric conduit fistula requires urgent surgical repair with viable muscle flap reinforcement; conduit ischemia at the anastomotic line necessitates conduit resection and delayed reconstruction. Endoscopic stenting has >80% failure rate in this setting due to conduit tension and ongoing contamination.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Thoracic Surgery", "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The clinical scenario describes a post-esophagectomy gastro-bronchial fistula with sepsis. The choice between options A (stenting) and B (surgical takedown/diversion) hinges critically on the viability of the gastric conduit. Current management guidelines generally favor endoscopic stenting (Option A) as the first-line treatment for fistulas with a viable conduit, reserving the high-morbidity surgical takedown (Option B) for cases with extensive conduit necrosis or stent failure. The stem states 'conduit mucosa visible,' which implies the tissue may be viable, yet the rationale justifies Option B by asserting 'conduit ischemia,' a finding not explicitly described in the vignette. Without definitive evidence of necrosis (e.g., 'dusky' or 'black' mucosa), Option A is a strong, arguably superior, competitor. The item is underspecified because the critical discriminator (conduit viability) required to rule out stenting and mandate surgical diversion is missing. Additionally, re-thoracotomy at day 18 (Option B) is extremely hazardous ('hostile chest'), making the threshold for selecting it very high.\",\"medical_accuracy_score\":\"3\",\"logical_validity\":false,\"logical_false_reason\":\"U\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The clinical scenario describes a post-esophagectomy gastro-bronchial fistula with sepsis. The choice between options A (stenting) and B (surgical takedown/diversion) hinges critically on the viability of the gastric conduit. Current management guidelines generally favor endoscopic stenting (Option A) as the first-line treatment for fistulas with a viable conduit, reserving the high-morbidity surgical takedown (Option B) for cases with extensive conduit necrosis or stent failure. The stem states 'conduit mucosa visible,' which implies the tissue may be viable, yet the rationale justifies Option B by asserting 'conduit ischemia,' a finding not explicitly described in the vignette. Without definitive evidence of necrosis (e.g., 'dusky' or 'black' mucosa), Option A is a strong, arguably superior, competitor. The item is underspecified because the critical discriminator (conduit viability) required to rule out stenting and mandate surgical diversion is missing. Additionally, re-thoracotomy at day 18 (Option B) is extremely hazardous ('hostile chest'), making the threshold for selecting it very high.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "U", "verdict": "FAIL", "fail_reason": "U"}, "judge_verdict": "FAIL", "judge_fail_reason": "U", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-002", "question": "A 54-year-old woman with antiphospholipid syndrome presents with 12 hours of severe epigastric pain and vomiting. CT angiography demonstrates thrombosis of the superior mesenteric vein extending into the intrahepatic portal veins, bowel wall thickening with pneumatosis of the proximal jejunum, and ascites. Exploratory laparotomy reveals dusky but viable small bowel without frank necrosis. What is the most appropriate next step?", "options": ["A) Resection of all affected bowel and mesenteric venous thrombectomy", "B) Systemic unfractionated heparin infusion targeting aPTT 2-3x control", "C) Catheter-directed thrombolysis of the superior mesenteric vein with alteplase via transhepatic approach", "D) Therapeutic enoxaparin 1 mg/kg twice daily and second-look laparotomy in 24 hours", "E) Mesenteric venous stent placement across the thrombosed segment"], "answer": "C", "answer_index": 2, "explanation": "In acute mesenteric venous thrombosis with bowel ischemia but viable intestine, catheter-directed thrombolysis restores venous outflow and prevents progression to infarction. Systemic anticoagulation alone is insufficient for extensive thrombus; surgical thrombectomy is ineffective and causes major bleeding.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Vascular Surgery", "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The item describes a patient with acute mesenteric venous thrombosis (MVT) who has just undergone exploratory laparotomy finding viable bowel. The keyed answer (C), catheter-directed thrombolysis (CDT), is medically inappropriate in this context. Recent major surgery (laparotomy) is a standard contraindication for thrombolytic therapy due to the high risk of postoperative hemorrhage. While CDT is a valid treatment for MVT in non-surgical candidates, initiating it immediately after a laparotomy is unsafe. The standard of care for MVT with viable bowel—especially in the immediate postoperative period—is systemic anticoagulation (Option B), typically with unfractionated heparin. Heparin prevents thrombus propagation while minimizing bleeding risk compared to thrombolytics and allows for rapid reversal if re-exploration is required. Option A is incorrect because the bowel is viable, so resection is not indicated. Option D is a reasonable alternative, but unfractionated heparin (B) is generally preferred over LMWH in unstable perioperative patients who may require second-look surgery. Because Option B is the widely accepted best answer and Option C is potentially dangerous in this specific setting, the item is miskeyed.\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The item describes a patient with acute mesenteric venous thrombosis (MVT) who has just undergone exploratory laparotomy finding viable bowel. The keyed answer (C), catheter-directed thrombolysis (CDT), is medically inappropriate in this context. Recent major surgery (laparotomy) is a standard contraindication for thrombolytic therapy due to the high risk of postoperative hemorrhage. While CDT is a valid treatment for MVT in non-surgical candidates, initiating it immediately after a laparotomy is unsafe. The standard of care for MVT with viable bowel—especially in the immediate postoperative period—is systemic anticoagulation (Option B), typically with unfractionated heparin. Heparin prevents thrombus propagation while minimizing bleeding risk compared to thrombolytics and allows for rapid reversal if re-exploration is required. Option A is incorrect because the bowel is viable, so resection is not indicated. Option D is a reasonable alternative, but unfractionated heparin (B) is generally preferred over LMWH in unstable perioperative patients who may require second-look surgery. Because Option B is the widely accepted best answer and Option C is potentially dangerous in this specific setting, the item is miskeyed.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-003", "question": "A 42-year-old man with MEN1 syndrome (germline MEN1 c.628_631del) is found to have a 2.8 cm duodenal gastrinoma with 3 regional periduodenal lymph node metastases on Ga-68 DOTATATE PET/CT. Serum gastrin is 2,200 pg/mL with gastric pH <2. He has no pancreatic lesions. What is the optimal surgical management?", "options": ["A) Whipple pancreaticoduodenectomy with pylorus preservation", "B) Pancreas-preserving duodenectomy with regional lymphadenectomy", "C) Endoscopic submucosal dissection of the duodenal tumor", "D) Long-acting octreotide 30 mg monthly without surgery", "E) Tumor enucleation through duodenotomy only"], "answer": "B", "answer_index": 1, "explanation": "For large duodenal neuroendocrine tumors in MEN1, pancreas-preserving duodenectomy achieves oncologic clearance while preserving pancreatic function, which is critical as these patients inevitably develop pancreatic neuroendocrine tumors requiring future pancreatic surgery. Whipple procedure is excessively morbid for duodenal disease alone.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The clinical vignette describes a patient with MEN1 syndrome and a large (2.8 cm) duodenal gastrinoma with regional lymph node metastases. The question asks for the optimal surgical management. The keyed answer, Pancreas-preserving duodenectomy (B), is a specialized procedure advocated by some experts to remove the gastrinoma-prone duodenum and clear regional nodes while preserving pancreatic parenchyma, which is advantageous in MEN1 patients prone to future pancreatic tumors. However, Option A (Whipple pancreaticoduodenectomy) is the widely accepted standard of care for large duodenal neuroendocrine tumors with nodal metastases in most international guidelines (e.g., NCCN, ENETS), particularly for tumors >2 cm where oncologic clearance is paramount. While the rationale correctly identifies the benefit of B, it incorrectly dismisses A as 'excessively morbid' relative to B; in reality, A is the standard, safe answer in most settings, while B is a niche, technically demanding option. Consequently, both A and B are defensible as the 'best' answer depending on whether one prioritizes standard guidelines (A) or theoretical organ preservation in expert hands (B). This creates a 'Multiple answers defensible' failure.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":false,\"logical_false_reason\":\"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The clinical vignette describes a patient with MEN1 syndrome and a large (2.8 cm) duodenal gastrinoma with regional lymph node metastases. The question asks for the optimal surgical management. The keyed answer, Pancreas-preserving duodenectomy (B), is a specialized procedure advocated by some experts to remove the gastrinoma-prone duodenum and clear regional nodes while preserving pancreatic parenchyma, which is advantageous in MEN1 patients prone to future pancreatic tumors. However, Option A (Whipple pancreaticoduodenectomy) is the widely accepted standard of care for large duodenal neuroendocrine tumors with nodal metastases in most international guidelines (e.g., NCCN, ENETS), particularly for tumors >2 cm where oncologic clearance is paramount. While the rationale correctly identifies the benefit of B, it incorrectly dismisses A as 'excessively morbid' relative to B; in reality, A is the standard, safe answer in most settings, while B is a niche, technically demanding option. Consequently, both A and B are defensible as the 'best' answer depending on whether one prioritizes standard guidelines (A) or theoretical organ preservation in expert hands (B). This creates a 'Multiple answers defensible' failure.", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-004", "question": "A 62-year-old man develops painful hepatomegaly, ascites, and jaundice 3 weeks after completing 6 cycles of FOLFOX adjuvant chemotherapy for colon cancer. Total bilirubin is 8.2 mg/dL, ALT 450 U/L, INR 1.8. Liver biopsy shows sinusoidal congestion, hepatocyte necrosis zone 3, and absence of portal inflammation. What is the definitive therapy?", "options": ["A) High-dose methylprednisolone 1 mg/kg/day and diuretics", "B) Defibrotide 25 mg/kg/day IV in divided doses for 21 days", "C) Transjugular intrahepatic portosystemic shunt (TIPS) placement", "D) N-acetylcysteine 150 mg/kg IV bolus then continuous infusion", "E) Urgent liver transplant evaluation"], "answer": "B", "answer_index": 1, "explanation": "Severe sinusoidal obstruction syndrome from oxaliplatin requires defibrotide, which restores thrombomodulin expression and promotes fibrinolysis. TIPS is contraindicated due to diffuse sinusoidal injury; steroids are ineffective. Transplant is reserved for fulminant hepatic failure with encephalopathy.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V (Valid)\\nVerdict on keyed answer: Correct best answer\\n\\nThe patient presents with classic signs of severe Sinusoidal Obstruction Syndrome (SOS), formerly Veno-Occlusive Disease (VOD): painful hepatomegaly, ascites, jaundice, and biopsy showing sinusoidal congestion/necrosis. While Oxaliplatin is a well-known cause of SOS (often 'blue liver' syndrome), the fulminant presentation described here is more typical of HSCT-associated SOS. However, given the diagnosis of severe SOS, Defibrotide (B) is the only disease-specific pharmacotherapy listed. Although FDA approval is specific to post-HSCT SOS with multi-organ dysfunction, Defibrotide is the intended best answer for treating the underlying pathology in a board-exam context. \\n\\nMedical accuracy is rated 3/5 because the vignette conflates the etiology (FOLFOX, where SOS is usually chronic/histologic or mild) with the phenotype (acute fulminant VOD usually seen in HSCT). Furthermore, Defibrotide is not standard 'definitive therapy' for non-HSCT cases in all guidelines (supportive care is primary). However, options A (steroids), C (TIPS, often contraindicated in acute severe SOS), and D (NAC) are incorrect. E (Transplant) is a last resort. Thus, B is the only defensible 'best' choice.\",\"medical_accuracy_score\":\"3\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V (Valid)\nVerdict on keyed answer: Correct best answer\n\nThe patient presents with classic signs of severe Sinusoidal Obstruction Syndrome (SOS), formerly Veno-Occlusive Disease (VOD): painful hepatomegaly, ascites, jaundice, and biopsy showing sinusoidal congestion/necrosis. While Oxaliplatin is a well-known cause of SOS (often 'blue liver' syndrome), the fulminant presentation described here is more typical of HSCT-associated SOS. However, given the diagnosis of severe SOS, Defibrotide (B) is the only disease-specific pharmacotherapy listed. Although FDA approval is specific to post-HSCT SOS with multi-organ dysfunction, Defibrotide is the intended best answer for treating the underlying pathology in a board-exam context. \n\nMedical accuracy is rated 3/5 because the vignette conflates the etiology (FOLFOX, where SOS is usually chronic/histologic or mild) with the phenotype (acute fulminant VOD usually seen in HSCT). Furthermore, Defibrotide is not standard 'definitive therapy' for non-HSCT cases in all guidelines (supportive care is primary). However, options A (steroids), C (TIPS, often contraindicated in acute severe SOS), and D (NAC) are incorrect. E (Transplant) is a last resort. Thus, B is the only defensible 'best' choice.", "medical_accuracy_score": 3, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-005", "question": "A 35-year-old woman with CFH p.Arg1215Gln mutation undergoes deceased donor kidney transplantation. On postoperative day 7, she develops rising creatinine (3.4 mg/dL), thrombocytopenia (45,000/μL), schistocytes, and hemolysis. Eculizumab 900 mg weekly was started preemptively on day 0. Platelets normalize by day 10 but creatinine continues to rise to 4.8 mg/dL. What is the next step?", "options": ["A) Increase eculizumab dose to 1,200 mg weekly", "B) Initiate daily plasma exchange with fresh frozen plasma", "C) Switch to ravulizumab 3,600 mg maintenance dose", "D) Measure eculizumab trough level and CH50 activity", "E) Proceed with transplant nephrectomy"], "answer": "D", "answer_index": 3, "explanation": "Breakthrough atypical HUS despite eculizumab requires therapeutic drug monitoring to distinguish underdosing from complement amplification via properdin or C5 gain-of-function mutation. Pharmacokinetic assessment guides therapy rather than empiric dose escalation or ineffective plasma exchange.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Nephrology", "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The item presents a classic scenario of post-transplant aHUS recurrence in a high-risk patient (CFH mutation) despite prophylactic eculizumab. The clinical picture is mixed: hematologic recovery (platelets normalized) but worsening renal function (rising creatinine). The core clinical question is whether the worsening renal function represents inadequate complement blockade (requiring dose adjustment) or another pathology (e.g., ATN, rejection, or drug toxicity). Option D is the correct best answer because measuring CH50 (to assess total complement activity) and eculizumab trough levels is required to distinguish between pharmacokinetic under-dosing and other causes of renal failure. If CH50 is fully suppressed (<10%), increasing the dose (Option A) is unnecessary and the clinician should look for other causes of graft dysfunction. If not suppressed, the dose is inadequate. Option B is inferior to C5 inhibition for aHUS. Option C is not the immediate next step without establishing the efficacy of the current C5 blockade. The item is medically accurate, aligns with standard guidelines for managing breakthrough TMA, and supports a unique best answer.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The item presents a classic scenario of post-transplant aHUS recurrence in a high-risk patient (CFH mutation) despite prophylactic eculizumab. The clinical picture is mixed: hematologic recovery (platelets normalized) but worsening renal function (rising creatinine). The core clinical question is whether the worsening renal function represents inadequate complement blockade (requiring dose adjustment) or another pathology (e.g., ATN, rejection, or drug toxicity). Option D is the correct best answer because measuring CH50 (to assess total complement activity) and eculizumab trough levels is required to distinguish between pharmacokinetic under-dosing and other causes of renal failure. If CH50 is fully suppressed (<10%), increasing the dose (Option A) is unnecessary and the clinician should look for other causes of graft dysfunction. If not suppressed, the dose is inadequate. Option B is inferior to C5 inhibition for aHUS. Option C is not the immediate next step without establishing the efficacy of the current C5 blockade. The item is medically accurate, aligns with standard guidelines for managing breakthrough TMA, and supports a unique best answer.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-006", "question": "A 28-year-old man is day +45 after matched unrelated donor allogeneic stem cell transplant for AML in CR1. He develops new hypertension (BP 165/100 mmHg), proteinuria (3.2 g/day), rising LDH (850 U/L), hemolysis, and thrombocytopenia. ADAMTS13 activity is 45%. Tacrolimus was stopped 14 days ago for rising creatinine. What is the appropriate therapy?", "options": ["A) Eculizumab 900 mg weekly IV", "B) High-dose methylprednisolone 1 g IV x3 days plus plasma exchange", "C) Rituximab 375 mg/m2 weekly for 4 doses", "D) Resume tacrolimus and target level 8-10 ng/mL", "E) Supportive care with aggressive blood pressure control only"], "answer": "A", "answer_index": 0, "explanation": "Transplant-associated thrombotic microangiopathy is mediated by complement activation independent of ADAMTS13; eculizumab blocks terminal complement and is the only effective therapy. Plasma exchange is ineffective; resuming calcineurin inhibitors worsens TMA.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Hematology", "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The vignette presents a classic case of Transplant-Associated Thrombotic Microangiopathy (TA-TMA) characterized by Microangiopathic Hemolytic Anemia (MAHA), thrombocytopenia, hypertension, and significant proteinuria in a post-HSCT patient. The ADAMTS13 activity of 45% definitively rules out Thrombotic Thrombocytopenic Purpura (TTP), which requires <10% activity; therefore, Plasma Exchange (Option B) and Rituximab (Option C) are inappropriate. Resuming Tacrolimus (Option D) is incorrect as Calcineurin Inhibitors are known triggers of TA-TMA. While supportive care and withdrawal of the offending agent (Option E) are first-line, this patient has high-risk features (nephrotic-range proteinuria) and progressive disease (rising LDH, new hypertension) despite having stopped Tacrolimus 14 days ago. In cases of high-risk or steroid/withdrawal-refractory TA-TMA, terminal complement blockade with Eculizumab (Option A) is the accepted best answer and standard of care. The item is logically sound and medically accurate.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The vignette presents a classic case of Transplant-Associated Thrombotic Microangiopathy (TA-TMA) characterized by Microangiopathic Hemolytic Anemia (MAHA), thrombocytopenia, hypertension, and significant proteinuria in a post-HSCT patient. The ADAMTS13 activity of 45% definitively rules out Thrombotic Thrombocytopenic Purpura (TTP), which requires <10% activity; therefore, Plasma Exchange (Option B) and Rituximab (Option C) are inappropriate. Resuming Tacrolimus (Option D) is incorrect as Calcineurin Inhibitors are known triggers of TA-TMA. While supportive care and withdrawal of the offending agent (Option E) are first-line, this patient has high-risk features (nephrotic-range proteinuria) and progressive disease (rising LDH, new hypertension) despite having stopped Tacrolimus 14 days ago. In cases of high-risk or steroid/withdrawal-refractory TA-TMA, terminal complement blockade with Eculizumab (Option A) is the accepted best answer and standard of care. The item is logically sound and medically accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-007", "question": "A 14-year-old girl with chronic atypical neutrophilic dermatosis, lipodystrophy, and recurrent fevers (CANDLE syndrome) has persistent inflammatory lesions and fevers despite anakinra 100 mg daily and canakinumab 150 mg monthly. Genetic testing confirms PSMB8 c.224C>T mutation. What is the next therapy?", "options": ["A) High-dose prednisone 1 mg/kg/day", "B) Baricitinib 4 mg daily (JAK1/2 inhibitor)", "C) Tocilizumab 8 mg/kg IV monthly", "D) Thalidomide 100 mg nightly", "E) Allogeneic stem cell transplant"], "answer": "B", "answer_index": 1, "explanation": "CANDLE syndrome is a type I interferonopathy due to proteasome dysfunction; JAK inhibitors block downstream interferon signaling and are effective when IL-1 blockade fails. Baricitinib has shown efficacy in refractory cases. Anti-IL-6 and thalidomide are ineffective; transplant is experimental.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Immunology", "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The item is medically accurate and logically sound. CANDLE syndrome (Chronic Atypical Neutrophilic Dermatosis with Lipodystrophy and Elevated temperature) is a proteasome-associated autoinflammatory syndrome (PRAAS) characterized by a Type I interferon signature. While IL-1 inhibitors (anakinra) are often tried initially, they frequently yield partial or poor responses, as described in the vignette. The mechanism-based treatment of choice for CANDLE syndrome, particularly after IL-1 failure, is JAK inhibition (e.g., baricitinib), which blocks the downstream signaling of Type I interferons (JAK-STAT pathway). This aligns with landmark studies (e.g., Montealegre Sanchez et al., NEJM 2018). High-dose prednisone (A) is not a sustainable long-term strategy due to toxicity, particularly exacerbating lipodystrophy. Tocilizumab (C) and thalidomide (D) do not target the primary pathogenic pathway effectively. Stem cell transplant (E) is reserved for severe, life-threatening cases refractory to medical therapy. Therefore, Baricitinib is the unique, defensible best answer.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The item is medically accurate and logically sound. CANDLE syndrome (Chronic Atypical Neutrophilic Dermatosis with Lipodystrophy and Elevated temperature) is a proteasome-associated autoinflammatory syndrome (PRAAS) characterized by a Type I interferon signature. While IL-1 inhibitors (anakinra) are often tried initially, they frequently yield partial or poor responses, as described in the vignette. The mechanism-based treatment of choice for CANDLE syndrome, particularly after IL-1 failure, is JAK inhibition (e.g., baricitinib), which blocks the downstream signaling of Type I interferons (JAK-STAT pathway). This aligns with landmark studies (e.g., Montealegre Sanchez et al., NEJM 2018). High-dose prednisone (A) is not a sustainable long-term strategy due to toxicity, particularly exacerbating lipodystrophy. Tocilizumab (C) and thalidomide (D) do not target the primary pathogenic pathway effectively. Stem cell transplant (E) is reserved for severe, life-threatening cases refractory to medical therapy. Therefore, Baricitinib is the unique, defensible best answer.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-008", "question": "A 38-year-old man from Vietnam with chronic mucocutaneous candidiasis is found to have STAT1 gain-of-function c.821T>C mutation. He presents with disseminated umbilicated papular skin lesions, hepatosplenomegaly, and fevers. Skin biopsy shows intracellular yeast forms with central septation. What is optimal therapy?", "options": ["A) Liposomal amphotericin B 5 mg/kg/day alone for 14 days", "B) Voriconazole 6 mg/kg IV q12h then 4 mg/kg maintenance", "C) Liposomal amphotericin B induction then itraconazole maintenance plus ruxolitinib 10 mg BID", "D) Caspofungin 70 mg loading then 50 mg daily", "E) Fluconazole 800 mg loading then 400 mg daily"], "answer": "C", "answer_index": 2, "explanation": "STAT1 GOF causes defective Th17 immunity leading to refractory dimorphic fungal infections. Talaromyces marneffei requires initial amphotericin induction followed by itraconazole maintenance. Adding JAK inhibition (ruxolitinib) reverses the underlying immunodeficiency and is essential for cure.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Infectious Disease", "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\n\\nThe vignette describes a classic presentation of disseminated Talaromyces marneffei infection (endemic to Vietnam, umbilicated papules resembling molluscum, hepatosplenomegaly) in a patient with STAT1 gain-of-function (GOF). The biopsy finding of intracellular yeast with central septation (binary fission) is pathognomonic for T. marneffei, distinguishing it from Histoplasma (budding). The standard treatment for severe/disseminated T. marneffei is induction with Liposomal Amphotericin B followed by prolonged maintenance with Itraconazole. Option A provides induction but explicitly excludes maintenance ('alone'), which is medically incorrect due to high relapse rates. Options B, D, and E suggest antifungal agents (Voriconazole, Caspofungin, Fluconazole) that are either ineffective or inferior to the standard of care for this specific pathogen. Option C is the only choice that includes the correct antifungal regimen (Amphotericin B induction + Itraconazole maintenance). Furthermore, it includes ruxolitinib, a JAK inhibitor that targets the underlying STAT1 GOF immunodeficiency, which is a supported adjunctive therapy to restore Th17 immunity. Because Option C is the only answer containing the correct antifungal standard of care, it is the unambiguous best answer.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\n\nThe vignette describes a classic presentation of disseminated Talaromyces marneffei infection (endemic to Vietnam, umbilicated papules resembling molluscum, hepatosplenomegaly) in a patient with STAT1 gain-of-function (GOF). The biopsy finding of intracellular yeast with central septation (binary fission) is pathognomonic for T. marneffei, distinguishing it from Histoplasma (budding). The standard treatment for severe/disseminated T. marneffei is induction with Liposomal Amphotericin B followed by prolonged maintenance with Itraconazole. Option A provides induction but explicitly excludes maintenance ('alone'), which is medically incorrect due to high relapse rates. Options B, D, and E suggest antifungal agents (Voriconazole, Caspofungin, Fluconazole) that are either ineffective or inferior to the standard of care for this specific pathogen. Option C is the only choice that includes the correct antifungal regimen (Amphotericin B induction + Itraconazole maintenance). Furthermore, it includes ruxolitinib, a JAK inhibitor that targets the underlying STAT1 GOF immunodeficiency, which is a supported adjunctive therapy to restore Th17 immunity. Because Option C is the only answer containing the correct antifungal standard of care, it is the unambiguous best answer.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-009", "question": "A 65-year-old man with metastatic melanoma on ipilimumab 3 mg/kg plus nivolumab 1 mg/kg presents with severe fatigue, hypotension (BP 85/50 mmHg), hyponatremia (Na 122 mEq/L), and headache. Troponin I is 15 ng/mL with normal EF 55%. Brain MRI shows diffuse pituitary enlargement with homogeneous enhancement. What is immediate management?", "options": ["A) Methylprednisolone 1 mg/kg/day IV alone", "B) Methylprednisolone 1 mg/kg/day plus infliximab 5 mg/kg", "C) Methylprednisolone 1 mg/kg/day plus mycophenolate mofetil 1 g BID", "D) Methylprednisolone 1 g IV x3 days plus anti-thymocyte globulin", "E) Hold immunotherapy and initiate supportive care only"], "answer": "C", "answer_index": 2, "explanation": "Combined hypophysitis and myocarditis from dual checkpoint inhibition requires high-dose steroids. Mycophenolate mofetil is preferred for steroid-refractory myocarditis as infliximab can worsen myocardial inflammation. Anti-thymocyte globulin is overly immunosuppressive in this setting.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Medical Oncology", "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: N (No answer defensible)\\nVerdict on keyed answer: No defensible answer\\n\\nThe patient presents with severe, life-threatening immune checkpoint inhibitor (ICI) myocarditis (Troponin 15 ng/mL, hypotension) and hypophysitis. Standard guidelines (ASCO, NCCN, SITC) recommend pulse-dose methylprednisolone (1 g/day) for Grade 3–4 or hemodynamically unstable myocarditis. The keyed answer (C) prescribes 1 mg/kg/day, which is inadequate for this severity, and adds mycophenolate mofetil (MMF) immediately. While MMF is the preferred second-line agent (avoiding infliximab, which is contraindicated in cardiac failure), it is typically reserved for steroid-refractory cases or started after 24 hours, not immediately alongside sub-therapeutic steroids. Additionally, the rationale explicitly states MMF is for 'steroid-refractory' cases, contradicting the key which selects it as immediate management. Option D offers the correct steroid dose but adds anti-thymocyte globulin (a 3rd-line agent) prematurely. Option A is underdosed. Thus, no option reflects the standard of care (Pulse steroids).\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"N\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: N (No answer defensible)\nVerdict on keyed answer: No defensible answer\n\nThe patient presents with severe, life-threatening immune checkpoint inhibitor (ICI) myocarditis (Troponin 15 ng/mL, hypotension) and hypophysitis. Standard guidelines (ASCO, NCCN, SITC) recommend pulse-dose methylprednisolone (1 g/day) for Grade 3–4 or hemodynamically unstable myocarditis. The keyed answer (C) prescribes 1 mg/kg/day, which is inadequate for this severity, and adds mycophenolate mofetil (MMF) immediately. While MMF is the preferred second-line agent (avoiding infliximab, which is contraindicated in cardiac failure), it is typically reserved for steroid-refractory cases or started after 24 hours, not immediately alongside sub-therapeutic steroids. Additionally, the rationale explicitly states MMF is for 'steroid-refractory' cases, contradicting the key which selects it as immediate management. Option D offers the correct steroid dose but adds anti-thymocyte globulin (a 3rd-line agent) prematurely. Option A is underdosed. Thus, no option reflects the standard of care (Pulse steroids).", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "N", "verdict": "FAIL", "fail_reason": "N"}, "judge_verdict": "FAIL", "judge_fail_reason": "N", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-010", "question": "A 42-year-old woman with lifelong idiopathic anaphylaxis, chronic urticaria, joint hypermobility, and baseline serum tryptase of 35 ng/mL is found to have heterozygous TPSAB1 copy number gain (α-tryptasemia). Symptoms persist despite high-dose cetirizine 40 mg daily and omalizumab 300 mg monthly. What is next therapy?", "options": ["A) Increase omalizumab to 600 mg monthly", "B) Prophylactic prednisone 10 mg daily", "C) Cromolyn sodium 200 mg QID", "D) Ketotifen 2 mg BID (mast cell stabilizer)", "E) Allergen immunotherapy based on skin testing"], "answer": "D", "answer_index": 3, "explanation": "Hereditary Alpha-Tryptasemia Syndrome causes constitutive mast cell activation; ketotifen stabilizes mast cell membranes and is effective when antihistamines fail. Omalizumab has variable efficacy; cromolyn is poorly absorbed systemically. Steroids are not prophylactic therapy.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Allergy/Immunology", "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The vignette describes a patient with Hereditary Alpha-Tryptasemia (HaT) presenting with systemic symptoms (anaphylaxis, urticaria) refractory to high-dose H1-antihistamines and standard-dose omalizumab. The question requires selecting the best adjunctive therapy. Option B (chronic steroids) is unsafe for prophylaxis. Option E (immunotherapy) is contraindicated in uncontrolled anaphylaxis and irrelevant for 'idiopathic' triggers. The discrimination relies on pharmacokinetics: Option C (Cromolyn) is poorly absorbed (<1%) and primarily effective for gastrointestinal symptoms, making it inferior for the patient's systemic presentation. Option D (Ketotifen) provides systemic mast cell stabilization and H1 blockade, making it mechanistically superior for anaphylaxis/urticaria. Although oral Ketotifen is not FDA-approved in the US (requiring compounding), it is a standard therapy in specialist management of mast cell disorders and the correct pharmacological answer here. Option A (increasing Omalizumab) is a consideration but typically follows the optimization of small-molecule stabilizers. The item is logically valid and medically accurate for a subspecialty context.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The vignette describes a patient with Hereditary Alpha-Tryptasemia (HaT) presenting with systemic symptoms (anaphylaxis, urticaria) refractory to high-dose H1-antihistamines and standard-dose omalizumab. The question requires selecting the best adjunctive therapy. Option B (chronic steroids) is unsafe for prophylaxis. Option E (immunotherapy) is contraindicated in uncontrolled anaphylaxis and irrelevant for 'idiopathic' triggers. The discrimination relies on pharmacokinetics: Option C (Cromolyn) is poorly absorbed (<1%) and primarily effective for gastrointestinal symptoms, making it inferior for the patient's systemic presentation. Option D (Ketotifen) provides systemic mast cell stabilization and H1 blockade, making it mechanistically superior for anaphylaxis/urticaria. Although oral Ketotifen is not FDA-approved in the US (requiring compounding), it is a standard therapy in specialist management of mast cell disorders and the correct pharmacological answer here. Option A (increasing Omalizumab) is a consideration but typically follows the optimization of small-molecule stabilizers. The item is logically valid and medically accurate for a subspecialty context.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-011", "question": "A 57-year-old man is 6 hours status post bilateral sequential lung transplantation for idiopathic pulmonary fibrosis. He remains on 100% FiO2 with PaO2/FiO2 ratio of 85 despite inhaled nitric oxide at 40 ppm and optimal ventilator settings. Chest X-ray shows diffuse bilateral infiltrates. What is the optimal mechanical support strategy?", "options": ["A) Veno-venous ECMO via femoral-jugular cannulation", "B) Veno-arterial ECMO via central cannulation", "C) Extracorporeal CO2 removal with 1 L/min blood flow", "D) Inhaled epoprostenol 50 ng/kg/min only", "E) Veno-venous ECMO via dual-lumen cannula (Avalon) in right internal jugular vein"], "answer": "E", "answer_index": 4, "explanation": "Severe primary graft dysfunction grade 3 requires full respiratory support. Dual-lumen single-site VV-ECMO (Avalon) allows early mobilization and rehabilitation, which improves long-term outcomes. Femoral-jugular configuration limits mobility; VA-ECMO is unnecessary without cardiac failure.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Thoracic Surgery", "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The clinical vignette describes a patient with severe Primary Graft Dysfunction (PGD) Grade 3, characterized by a PaO2/FiO2 ratio < 100 and diffuse infiltrates 6 hours after lung transplantation. The patient has refractory hypoxemia despite optimal conventional management (100% FiO2, iNO), necessitating extracorporeal life support. Since there is no indication of hemodynamic instability or right ventricular failure, Veno-Venous (VV) ECMO is the appropriate modality, making Veno-Arterial (VA) ECMO (Option B) unnecessary and potentially more invasive. Option C is insufficient for severe hypoxemia. The critical discrimination lies between Option A (Femoral-Jugular VV-ECMO) and Option E (Dual-lumen IJ VV-ECMO). In the context of lung transplantation, early mobilization and rehabilitation are paramount for graft survival and functional recovery. A dual-lumen single-site cannula (Avalon) in the internal jugular vein facilitates ambulation ('ambulatory ECMO'), whereas femoral cannulation significantly restricts mobility. Therefore, Option E represents the 'optimal' strategy for this specific patient population, aligning with current transplant critical care standards. The item is logically valid, medically accurate, and tests a specific, high-yield management principle.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The clinical vignette describes a patient with severe Primary Graft Dysfunction (PGD) Grade 3, characterized by a PaO2/FiO2 ratio < 100 and diffuse infiltrates 6 hours after lung transplantation. The patient has refractory hypoxemia despite optimal conventional management (100% FiO2, iNO), necessitating extracorporeal life support. Since there is no indication of hemodynamic instability or right ventricular failure, Veno-Venous (VV) ECMO is the appropriate modality, making Veno-Arterial (VA) ECMO (Option B) unnecessary and potentially more invasive. Option C is insufficient for severe hypoxemia. The critical discrimination lies between Option A (Femoral-Jugular VV-ECMO) and Option E (Dual-lumen IJ VV-ECMO). In the context of lung transplantation, early mobilization and rehabilitation are paramount for graft survival and functional recovery. A dual-lumen single-site cannula (Avalon) in the internal jugular vein facilitates ambulation ('ambulatory ECMO'), whereas femoral cannulation significantly restricts mobility. Therefore, Option E represents the 'optimal' strategy for this specific patient population, aligning with current transplant critical care standards. The item is logically valid, medically accurate, and tests a specific, high-yield management principle.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-012", "question": "A 72-year-old man has a 5.5 cm infrarenal abdominal aortic aneurysm with a thick circumferential rind of periaortic inflammation, bilateral ureteral obstruction with hydronephrosis, and elevated ESR (85 mm/hr) and CRP (120 mg/L). What is the optimal management sequence?", "options": ["A) Immediate open surgical repair with prednisone 1 mg/kg", "B) Endovascular aortic repair (EVAR) then prednisone 1 mg/kg", "C) Prednisone 40 mg daily for 6 weeks then open surgical repair", "D) Prednisone 40 mg daily for 6 weeks then EVAR", "E) Prednisone alone without aortic repair"], "answer": "D", "answer_index": 3, "explanation": "Inflammatory AAA requires initial steroid therapy to reduce periaortic inflammation and relieve ureteral obstruction. Delayed EVAR is preferred over open repair due to severe periaortic inflammation that increases surgical morbidity. Steroids alone risk aneurysm rupture.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Vascular Surgery", "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The clinical vignette describes a symptomatic 5.5 cm inflammatory abdominal aortic aneurysm (IAAA) with ureteral obstruction. The keyed answer (D) proposes a 6-week course of high-dose steroids followed by EVAR. This management strategy is medically controversial and potentially unsafe. A 5.5 cm aneurysm is at the size threshold for repair, and the patient is symptomatic; delaying repair for 6 weeks while administering corticosteroids (which can weaken the aortic wall) significantly increases the risk of rupture. Modern guidelines (e.g., ESVS, SVS) recommend EVAR as the first-line treatment for IAAA because it avoids the morbidity of open repair in a 'hostile abdomen' and typically leads to regression of the inflammatory mass and relief of ureteral obstruction without the need for prolonged preoperative steroids. Option B (EVAR then prednisone) represents a safer, more standard sequence: securing the aneurysm first to prevent rupture, then using steroids adjunctively if inflammation/obstruction persists. Because Option B is clinically superior (prioritizing rupture prevention) but the key is D, the item is classified as miskeyed. The question likely relies on older dogma regarding downstaging inflammation prior to *open* repair, which is less applicable to EVAR and hazardous for a large aneurysm.\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The clinical vignette describes a symptomatic 5.5 cm inflammatory abdominal aortic aneurysm (IAAA) with ureteral obstruction. The keyed answer (D) proposes a 6-week course of high-dose steroids followed by EVAR. This management strategy is medically controversial and potentially unsafe. A 5.5 cm aneurysm is at the size threshold for repair, and the patient is symptomatic; delaying repair for 6 weeks while administering corticosteroids (which can weaken the aortic wall) significantly increases the risk of rupture. Modern guidelines (e.g., ESVS, SVS) recommend EVAR as the first-line treatment for IAAA because it avoids the morbidity of open repair in a 'hostile abdomen' and typically leads to regression of the inflammatory mass and relief of ureteral obstruction without the need for prolonged preoperative steroids. Option B (EVAR then prednisone) represents a safer, more standard sequence: securing the aneurysm first to prevent rupture, then using steroids adjunctively if inflammation/obstruction persists. Because Option B is clinically superior (prioritizing rupture prevention) but the key is D, the item is classified as miskeyed. The question likely relies on older dogma regarding downstaging inflammation prior to *open* repair, which is less applicable to EVAR and hazardous for a large aneurysm.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-013", "question": "A 58-year-old woman presents with a 4 cm pancreatic tail tumor, necrolytic migratory erythema, weight loss of 30 lbs, and new-onset diabetes. Biopsy confirms glucagonoma with Ki-67 8% and diffuse hepatic metastases on MRI. Serum glucagon is 2,500 pg/mL. What is first-line therapy?", "options": ["A) Distal pancreatectomy with splenectomy", "B) Octreotide LAR 30 mg intramuscular monthly", "C) Lanreotide autogel 120 mg deep subcutaneous every 4 weeks", "D) Everolimus 10 mg daily plus octreotide LAR", "E) Streptozocin 500 mg/m2 plus doxorubicin 50 mg/m2 every 3 weeks"], "answer": "C", "answer_index": 2, "explanation": "For metastatic glucagonoma, long-acting somatostatin analogs control hormone symptoms and have antiproliferative activity. Lanreotide 120 mg every 4 weeks is preferred over octreotide LAR due to consistent dosing. Everolimus is second-line; chemotherapy is reserved for progressive disease.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The clinical vignette describes a patient with metastatic glucagonoma (Grade 2, Ki-67 8%) presenting with classic symptoms (necrolytic migratory erythema, diabetes). The question asks for first-line therapy. Somatostatin analogs (SSAs) are the standard first-line treatment for symptom control and tumor stabilization in functional, well-differentiated metastatic neuroendocrine tumors. However, both Option B (Octreotide LAR) and Option C (Lanreotide) are standard-of-care SSAs used for this indication. Major guidelines (NCCN, ENETS, NANETS) generally consider them interchangeable options with comparable efficacy for symptom and tumor control. The rationale's claim that Lanreotide is preferred due to 'consistent dosing' is not a sufficiently strong medical consensus to render Octreotide LAR incorrect. Therefore, the item has two equally defensible correct answers. To fix, one of the SSA options should be removed or replaced with a clearly incorrect mechanism (e.g., short-acting octreotide only, or a different drug class).\",\"medical_accuracy_score\":\"4\",\"logical_validity\":false,\"logical_false_reason\":\"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The clinical vignette describes a patient with metastatic glucagonoma (Grade 2, Ki-67 8%) presenting with classic symptoms (necrolytic migratory erythema, diabetes). The question asks for first-line therapy. Somatostatin analogs (SSAs) are the standard first-line treatment for symptom control and tumor stabilization in functional, well-differentiated metastatic neuroendocrine tumors. However, both Option B (Octreotide LAR) and Option C (Lanreotide) are standard-of-care SSAs used for this indication. Major guidelines (NCCN, ENETS, NANETS) generally consider them interchangeable options with comparable efficacy for symptom and tumor control. The rationale's claim that Lanreotide is preferred due to 'consistent dosing' is not a sufficiently strong medical consensus to render Octreotide LAR incorrect. Therefore, the item has two equally defensible correct answers. To fix, one of the SSA options should be removed or replaced with a clearly incorrect mechanism (e.g., short-acting octreotide only, or a different drug class).", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-014", "question": "A 35-year-old woman has chronic iron deficiency anemia requiring IV iron every 3 months, recurrent episodes of partial small bowel obstruction, and capsule endoscopy shows 5 short ulcerated strictures in the proximal jejunum. Biopsy shows superficial ulceration without granulomas, crypt distortion, or viral inclusions. What is the diagnosis and treatment?", "options": ["A) Crohn's disease: start infliximab", "B) NSAID enteropathy: stop all NSAIDs", "C) Cryptogenic multifocal ulcerous stenosing enteritis: budesonide 9 mg daily", "D) Small bowel lymphoma: R-CHOP chemotherapy", "E) Refractory celiac disease: cladribine"], "answer": "C", "answer_index": 2, "explanation": "Cryptogenic multifocal ulcerous stenosing enteritis (CMUSE) is characterized by multiple short ulcerated strictures without transmural inflammation. Diagnosis requires exclusion of Crohn's disease and NSAID injury. Budesonide induces remission; anti-TNF agents are ineffective. Capsule retention risk requires patency assessment.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The clinical vignette describes a patient with recurrent small bowel obstruction, iron deficiency anemia, and 'short ulcerated strictures' in the proximal jejunum. The biopsy findings (superficial ulceration, no granulomas, no crypt distortion) are intended to rule out Crohn's disease (Option A) and point towards Cryptogenic Multifocal Ulcerous Stenosing Enteritis (CMUSE), a rare diagnosis of exclusion. However, the stem fails to exclude the most common cause of this presentation: NSAID-induced enteropathy (Option B). NSAID enteropathy presents with identical clinical and histological features (strictures/diaphragms, superficial ulceration, anemia). Without an explicit history denying NSAID use, Option B is a statistically more probable diagnosis than the rare CMUSE, and 'Stop all NSAIDs' would be the correct first-line management. Consequently, both B and C are defensible depending on the unstated medication history. Additionally, the keyed treatment (Budesonide) is typically formulated for ileal/colonic release and may not effectively treat strictures in the proximal jejunum, making the key medically suboptimal compared to systemic steroids. The item is underspecified, leading to multiple defensible answers.\",\"medical_accuracy_score\":\"3\",\"logical_validity\":false,\"logical_false_reason\":\"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The clinical vignette describes a patient with recurrent small bowel obstruction, iron deficiency anemia, and 'short ulcerated strictures' in the proximal jejunum. The biopsy findings (superficial ulceration, no granulomas, no crypt distortion) are intended to rule out Crohn's disease (Option A) and point towards Cryptogenic Multifocal Ulcerous Stenosing Enteritis (CMUSE), a rare diagnosis of exclusion. However, the stem fails to exclude the most common cause of this presentation: NSAID-induced enteropathy (Option B). NSAID enteropathy presents with identical clinical and histological features (strictures/diaphragms, superficial ulceration, anemia). Without an explicit history denying NSAID use, Option B is a statistically more probable diagnosis than the rare CMUSE, and 'Stop all NSAIDs' would be the correct first-line management. Consequently, both B and C are defensible depending on the unstated medication history. Additionally, the keyed treatment (Budesonide) is typically formulated for ileal/colonic release and may not effectively treat strictures in the proximal jejunum, making the key medically suboptimal compared to systemic steroids. The item is underspecified, leading to multiple defensible answers.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-015", "question": "A 45-year-old HIV-positive man on tenofovir DF/emtricitabine for 10 years presents with proximal muscle weakness, bone pain, and hypophosphatemia of 1.8 mg/dL. Urine studies show phosphaturia, glucosuria with normal blood glucose, and metabolic acidosis. What is the optimal electrolyte replacement regimen?", "options": ["A) Oral sodium phosphate 1 g TID alone", "B) Oral sodium phosphate plus calcitriol 0.25 mcg daily", "C) IV sodium phosphate 0.16 mmol/kg bolus then oral phosphate", "D) Oral sodium phosphate plus sodium bicarbonate 650 mg TID", "E) Stop tenofovir only"], "answer": "D", "answer_index": 3, "explanation": "Tenofovir-induced Fanconi syndrome causes proximal tubular loss of phosphate, glucose, and bicarbonate. Replacement requires both phosphate and bicarbonate to correct metabolic acidosis and prevent osteomalacia. Calcitriol is unnecessary if 25-OH vitamin D is normal; stopping tenofovir is necessary but insufficient for severe deficiency.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Nephrology", "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The vignette describes a classic case of Tenofovir Disoproxil Fumarate (TDF)-induced Fanconi syndrome, characterized by proximal tubular dysfunction resulting in urinary wasting of phosphate, glucose, and bicarbonate (Type 2 Renal Tubular Acidosis). The patient presents with symptomatic moderate hypophosphatemia (1.8 mg/dL) and metabolic acidosis. The question specifically asks for the 'optimal electrolyte replacement regimen.' This phrasing excludes Option E (stopping TDF), which is the definitive management of the underlying cause but not an electrolyte replacement regimen itself. Among the replacement options, the patient requires both phosphate (for hypophosphatemia/bone pain) and alkali (for acidosis). Option D is the only choice that provides both phosphate and bicarbonate. Option A ignores the acidosis. Option B includes calcitriol; while activated Vitamin D production can be impaired in proximal tubule injury, correcting the documented metabolic acidosis is a standard priority in Fanconi syndrome, making D superior to B. Option C (IV phosphate) is unnecessarily aggressive and risky for a level of 1.8 mg/dL. Although the bicarbonate dose in Option D (~23 mEq/day) is clinically low for Type 2 RTA (which often requires massive alkali loads), it is the only qualitatively correct combination.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The vignette describes a classic case of Tenofovir Disoproxil Fumarate (TDF)-induced Fanconi syndrome, characterized by proximal tubular dysfunction resulting in urinary wasting of phosphate, glucose, and bicarbonate (Type 2 Renal Tubular Acidosis). The patient presents with symptomatic moderate hypophosphatemia (1.8 mg/dL) and metabolic acidosis. The question specifically asks for the 'optimal electrolyte replacement regimen.' This phrasing excludes Option E (stopping TDF), which is the definitive management of the underlying cause but not an electrolyte replacement regimen itself. Among the replacement options, the patient requires both phosphate (for hypophosphatemia/bone pain) and alkali (for acidosis). Option D is the only choice that provides both phosphate and bicarbonate. Option A ignores the acidosis. Option B includes calcitriol; while activated Vitamin D production can be impaired in proximal tubule injury, correcting the documented metabolic acidosis is a standard priority in Fanconi syndrome, making D superior to B. Option C (IV phosphate) is unnecessarily aggressive and risky for a level of 1.8 mg/dL. Although the bicarbonate dose in Option D (~23 mEq/day) is clinically low for Type 2 RTA (which often requires massive alkali loads), it is the only qualitatively correct combination.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-016", "question": "A 70-year-old man with coronary artery disease is found to have clonal hematopoiesis of indeterminate potential (CHIP) with JAK2 V617F mutation at variant allele frequency of 12% on peripheral blood NGS. CBC is normal and there is no splenomegaly. What is his annual risk of thrombosis and recommended prophylaxis?", "options": ["A) 1% annual thrombosis risk; no prophylaxis needed", "B) 5% annual thrombosis risk; start hydroxyurea", "C) 0.5% annual thrombosis risk; start low-dose aspirin", "D) 10% annual thrombosis risk; start therapeutic enoxaparin", "E) No increased thrombosis risk; no prophylaxis"], "answer": "C", "answer_index": 2, "explanation": "CHIP with JAK2 V617F confers a 0.5-1% annual risk of thrombosis independent of traditional risk factors. Low-dose aspirin is recommended for primary prophylaxis. Progression to myelofibrosis or AML is rare (<1% annually). Hydroxyurea is not indicated without overt myeloproliferative neoplasm.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Hematology", "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The question presents a patient with Coronary Artery Disease (CAD) and JAK2 V617F CHIP. The most critical clinical determinant here is the history of CAD, which is a standard indication for aspirin (secondary prevention) regardless of the CHIP status. Therefore, options A and E ('no prophylaxis') are medically incorrect for a patient with established CAD. Options B (hydroxyurea) and D (enoxaparin) are inappropriate for CHIP with normal blood counts (no overt MPN) and no acute thrombosis. Option C is the only clinically defensible management plan ('start low-dose aspirin'). While the precise annual thrombotic risk of JAK2 CHIP is variable in literature (often cited as ~1% or an odds ratio of ~2x), the management decision allows for a unique best answer. The explanation's assertion that aspirin is recommended for 'primary prophylaxis' of CHIP is debated in the absence of CV risk factors, but given the patient's CAD, the indication is absolute. The item is logically valid.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The question presents a patient with Coronary Artery Disease (CAD) and JAK2 V617F CHIP. The most critical clinical determinant here is the history of CAD, which is a standard indication for aspirin (secondary prevention) regardless of the CHIP status. Therefore, options A and E ('no prophylaxis') are medically incorrect for a patient with established CAD. Options B (hydroxyurea) and D (enoxaparin) are inappropriate for CHIP with normal blood counts (no overt MPN) and no acute thrombosis. Option C is the only clinically defensible management plan ('start low-dose aspirin'). While the precise annual thrombotic risk of JAK2 CHIP is variable in literature (often cited as ~1% or an odds ratio of ~2x), the management decision allows for a unique best answer. The explanation's assertion that aspirin is recommended for 'primary prophylaxis' of CHIP is debated in the absence of CV risk factors, but given the patient's CAD, the indication is absolute. The item is logically valid.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-017", "question": "A 22-year-old man has recurrent sinopulmonary infections with Streptococcus pneumoniae, systemic lupus erythematosus-like malar rash, and low C1q level of 5 mg/dL (normal 10-25) with normal C1r and C1s. Genetic testing shows homozygous C1QA c.150C>G mutation. What is the recommended infection prophylaxis?", "options": ["A) Penicillin V 250 mg BID lifelong", "B) IVIG 400 mg/kg monthly", "C) No prophylaxis needed", "D) Posaconazole 300 mg daily", "E) Pneumococcal vaccine only"], "answer": "A", "answer_index": 0, "explanation": "C1q deficiency causes impaired classical pathway opsonization of encapsulated organisms and SLE-like autoimmunity. Lifelong penicillin prophylaxis is recommended to prevent invasive pneumococcal disease. IVIG is not indicated unless specific antibody deficiency coexists; fungal prophylaxis is unnecessary.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Immunology", "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The vignette describes a classic presentation of hereditary C1q deficiency: SLE-like autoimmunity and susceptibility to encapsulated bacteria (specifically Streptococcus pneumoniae) due to a defect in the classical complement pathway. Management of complement deficiencies primarily involves vaccination against encapsulated organisms (pneumococcus, meningococcus, Hib). However, for patients with 'recurrent' infections (as stated in the stem), antibiotic prophylaxis is the standard next step in management to prevent sepsis, similar to asplenia management. Option A (Penicillin V) is the appropriate agent and dosing for pneumococcal prophylaxis. Option B (IVIG) is incorrect as the defect is not antibody-mediated, and IVIG does not replenish complement. Option D (Posaconazole) targets fungi, which are not the primary risk. Option E (Pneumococcal vaccine only) is incorrect because the qualifier 'only' excludes other necessary vaccines (Meningococcal, Hib) and excludes the antibiotic prophylaxis indicated by the patient's history of recurrence. Therefore, A is the single best answer.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The vignette describes a classic presentation of hereditary C1q deficiency: SLE-like autoimmunity and susceptibility to encapsulated bacteria (specifically Streptococcus pneumoniae) due to a defect in the classical complement pathway. Management of complement deficiencies primarily involves vaccination against encapsulated organisms (pneumococcus, meningococcus, Hib). However, for patients with 'recurrent' infections (as stated in the stem), antibiotic prophylaxis is the standard next step in management to prevent sepsis, similar to asplenia management. Option A (Penicillin V) is the appropriate agent and dosing for pneumococcal prophylaxis. Option B (IVIG) is incorrect as the defect is not antibody-mediated, and IVIG does not replenish complement. Option D (Posaconazole) targets fungi, which are not the primary risk. Option E (Pneumococcal vaccine only) is incorrect because the qualifier 'only' excludes other necessary vaccines (Meningococcal, Hib) and excludes the antibiotic prophylaxis indicated by the patient's history of recurrence. Therefore, A is the single best answer.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-018", "question": "A 68-year-old man on deferoxamine for transfusional iron overload (ferritin 3,500 ng/mL) develops a cavitary right upper lobe lung lesion. Biopsy shows broad nonseptate hyphae with right-angle branching. What is the optimal antifungal combination therapy?", "options": ["A) Liposomal amphotericin B 5 mg/kg/day alone", "B) Amphotericin B plus posaconazole 300 mg daily", "C) Isavuconazole 372 mg daily", "D) Amphotericin B plus deferasirox 20 mg/kg daily", "E) Caspofungin 50 mg daily plus posaconazole"], "answer": "D", "answer_index": 3, "explanation": "Deferoxamine is a siderophore that enhances mucoraceal growth and must be stopped. Deferasirox has intrinsic antifungal activity against Mucorales. Liposomal amphotericin B is first-line; combination with deferasirox improves outcomes. Isavuconazole is second-line monotherapy; caspofungin has minimal activity.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Infectious Disease", "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The clinical vignette describes a patient with mucormycosis (Zygomycosis) characterized by broad, nonseptate hyphae with right-angle branching, precipitated by deferoxamine (which acts as a siderophore for Mucorales). The keyed answer (D) recommends adding deferasirox. This is based on outdated hypotheses; the landmark DEFEAT-MUCOR randomized controlled trial (2015) demonstrated that adjunctive deferasirox significantly increased mortality (82% vs 22%) in patients with mucormycosis. Therefore, the keyed answer is medically contraindicated and dangerous. The current gold standard for induction is high-dose liposomal amphotericin B (Option A) combined with surgical debridement. However, the question stem specifically asks for 'optimal antifungal combination therapy,' which technically excludes Option A (monotherapy). Option B (AmB + Posaconazole) is a combination but is not standard first-line care (weak evidence). Consequently, no option is defensible: the intended key is harmful, and the actual standard of care (A) contradicts the 'combination' constraint in the stem. The item relies on obsolete medical knowledge that poses a safety risk.\",\"medical_accuracy_score\":\"1\",\"logical_validity\":false,\"logical_false_reason\":\"N\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The clinical vignette describes a patient with mucormycosis (Zygomycosis) characterized by broad, nonseptate hyphae with right-angle branching, precipitated by deferoxamine (which acts as a siderophore for Mucorales). The keyed answer (D) recommends adding deferasirox. This is based on outdated hypotheses; the landmark DEFEAT-MUCOR randomized controlled trial (2015) demonstrated that adjunctive deferasirox significantly increased mortality (82% vs 22%) in patients with mucormycosis. Therefore, the keyed answer is medically contraindicated and dangerous. The current gold standard for induction is high-dose liposomal amphotericin B (Option A) combined with surgical debridement. However, the question stem specifically asks for 'optimal antifungal combination therapy,' which technically excludes Option A (monotherapy). Option B (AmB + Posaconazole) is a combination but is not standard first-line care (weak evidence). Consequently, no option is defensible: the intended key is harmful, and the actual standard of care (A) contradicts the 'combination' constraint in the stem. The item relies on obsolete medical knowledge that poses a safety risk.", "medical_accuracy_score": 1, "logical_validity": false, "logical_false_reason": "N", "verdict": "FAIL", "fail_reason": "N"}, "judge_verdict": "FAIL", "judge_fail_reason": "N", "judge_medical_accuracy_score": 1}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-019", "question": "A 62-year-old woman with high-grade serous ovarian cancer develops subacute cerebellar ataxia, dysarthria, and nystagmus over 3 weeks. Anti-Yo antibodies are positive at titer 1:10,240 in serum and CSF. CSF shows lymphocytic pleocytosis (50 cells/μL). What is the immunotherapy protocol?", "options": ["A) Methylprednisolone 1 g IV x3 days then prednisone 1 mg/kg", "B) IVIG 2 g/kg monthly", "C) Cyclophosphamide 750 mg/m2 monthly plus prednisone", "D) Rituximab 375 mg/m2 weekly x4 plus prednisone", "E) Tumor debulking surgery only"], "answer": "C", "answer_index": 2, "explanation": "Anti-Yo associated paraneoplastic cerebellar degeneration is B-cell mediated; cyclophosphamide crosses the blood-brain barrier and depletes plasma cells more effectively than rituximab. Combined with steroids, it stabilizes neurologic decline. IVIG is less effective for anti-Yo; tumor treatment alone is insufficient.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Medical Oncology", "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V (Valid)\\nVerdict on keyed answer: Correct best answer (in the context of board exam heuristics)\\n\\nThe vignette describes a classic case of Anti-Yo paraneoplastic cerebellar degeneration (PCD). The key to answering is recognizing that Anti-Yo targets an intracellular antigen (CDR2), and the associated pathology is primarily T-cell mediated (cytotoxic CD8+ T-cells), unlike surface-antigen syndromes (e.g., NMDA) which are antibody-mediated. \\n\\nStandard board-exam logic distinguishes treatment based on this pathophysiology: Surface antigens respond to antibody-depleting therapies (IVIG, PLEX, Rituximab), while intracellular antigens (Yo, Hu) are notoriously refractory but, if treated, require agents that target T-cell cytotoxicity (e.g., Cyclophosphamide). Therefore, Option C (Cyclophosphamide) is the best answer among the choices, as Options A, B, and D are primarily directed at humoral mechanisms or are less potent against T-cell effectors. Option E is incorrect because immunotherapy is indicated alongside surgery.\\n\\nMedical Accuracy Issue: The provided author rationale contains a significant error, stating Anti-Yo is \\\"B-cell mediated.\\\" It is T-cell mediated. However, the conclusion (Cyclophosphamide) remains the correct exam answer because Cyclophosphamide is a broad immunosuppressant effective against T-cells, whereas Rituximab (B-cell specific) is theoretically less ideal for T-cell mediated damage, despite being used in practice.\",\"medical_accuracy_score\":\"3\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V (Valid)\nVerdict on keyed answer: Correct best answer (in the context of board exam heuristics)\n\nThe vignette describes a classic case of Anti-Yo paraneoplastic cerebellar degeneration (PCD). The key to answering is recognizing that Anti-Yo targets an intracellular antigen (CDR2), and the associated pathology is primarily T-cell mediated (cytotoxic CD8+ T-cells), unlike surface-antigen syndromes (e.g., NMDA) which are antibody-mediated. \n\nStandard board-exam logic distinguishes treatment based on this pathophysiology: Surface antigens respond to antibody-depleting therapies (IVIG, PLEX, Rituximab), while intracellular antigens (Yo, Hu) are notoriously refractory but, if treated, require agents that target T-cell cytotoxicity (e.g., Cyclophosphamide). Therefore, Option C (Cyclophosphamide) is the best answer among the choices, as Options A, B, and D are primarily directed at humoral mechanisms or are less potent against T-cell effectors. Option E is incorrect because immunotherapy is indicated alongside surgery.\n\nMedical Accuracy Issue: The provided author rationale contains a significant error, stating Anti-Yo is \"B-cell mediated.\" It is T-cell mediated. However, the conclusion (Cyclophosphamide) remains the correct exam answer because Cyclophosphamide is a broad immunosuppressant effective against T-cells, whereas Rituximab (B-cell specific) is theoretically less ideal for T-cell mediated damage, despite being used in practice.", "medical_accuracy_score": 3, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-020", "question": "A 35-year-old man develops fever, facial edema, diffuse erythematous rash covering 60% BSA, eosinophilia of 2,200/μL, and atypical lymphocytes 3 weeks after starting allopurinol 300 mg daily for gout. AST is 850 U/L and ALT is 620 U/L. What is the appropriate corticosteroid regimen?", "options": ["A) Prednisone 1 mg/kg PO daily, taper over 2 weeks", "B) Methylprednisolone 1-2 mg/kg IV, slow taper over 8-12 weeks", "C) Methylprednisolone 1 g IV x3 days only", "D) No steroids; antihistamines and topical therapy", "E) Topical triamcinolone 0.1% BSA"], "answer": "B", "answer_index": 1, "explanation": "DRESS syndrome with hepatitis requires high-dose systemic steroids; rapid taper risks relapse and rebound hepatitis. Slow taper over 8-12 weeks with monitoring for viral reactivation (HHV-6) is standard. Pulse therapy alone is insufficient; antihistamines are adjunctive only.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Allergy/Immunology", "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The vignette describes a classic case of DRESS syndrome (Drug Reaction with Eosinophilia and Systemic Symptoms) triggered by allopurinol, evidenced by the triad of fever, rash, and internal organ involvement (severe hepatitis with AST/ALT >5x ULN), alongside eosinophilia and atypical lymphocytes. The timing (3 weeks post-initiation) is characteristic. The primary teaching point concerns the management of DRESS with severe visceral involvement. Current guidelines mandate systemic corticosteroids with a very slow taper (minimum 6–8 weeks, often longer) because rapid withdrawal is strongly associated with relapse and rebound hepatitis. Option A suggests a 2-week taper, which is dangerously short and contraindicated. Option B correctly identifies the need for systemic steroids (IV methylprednisolone is appropriate for severe hepatitis) and, most importantly, specifies the required slow taper of 8–12 weeks. Options D and E are insufficient for life-threatening systemic hypersensitivity. Option C (pulse dose without taper) fails to address the maintenance requirement. The item is medically accurate, the distractors are well-differentiated by the taper duration, and the key is supported by standard of care.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The vignette describes a classic case of DRESS syndrome (Drug Reaction with Eosinophilia and Systemic Symptoms) triggered by allopurinol, evidenced by the triad of fever, rash, and internal organ involvement (severe hepatitis with AST/ALT >5x ULN), alongside eosinophilia and atypical lymphocytes. The timing (3 weeks post-initiation) is characteristic. The primary teaching point concerns the management of DRESS with severe visceral involvement. Current guidelines mandate systemic corticosteroids with a very slow taper (minimum 6–8 weeks, often longer) because rapid withdrawal is strongly associated with relapse and rebound hepatitis. Option A suggests a 2-week taper, which is dangerously short and contraindicated. Option B correctly identifies the need for systemic steroids (IV methylprednisolone is appropriate for severe hepatitis) and, most importantly, specifies the required slow taper of 8–12 weeks. Options D and E are insufficient for life-threatening systemic hypersensitivity. Option C (pulse dose without taper) fails to address the maintenance requirement. The item is medically accurate, the distractors are well-differentiated by the taper duration, and the key is supported by standard of care.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]